Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies
American Journal of Health-System Pharmacy · 08.02.2024 · 81 (4) · 112-119
DOI: 10.1093/ajhp/zxad210 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Health-System Pharmacy, online erschienen am 07.09.2023. Verfasst von Kenneth Tham und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Fred Hutchinson Cancer Center, Seattle, WA, USA. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms, Anti-Infective Agents, Pneumonia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Purpose
Ibrutinib is a Bruton’s tyrosine kinase inhibitor used to treat multiple hematologic malignancies and graft-versus-host disease. Though less myelosuppressive than cytotoxic chemotherapy, increased infections, including invasive fungal infections (IFIs), have been reported with ibrutinib use. This study aimed to determine the characteristics and risk factors for infection associated with ibrutinib at our institution.
Methods
Patients who received ibrutinib between June 2014 and August 2019 were included. Primary endpoints were the incidence of any infection and the incidence of serious infection (defined as hospitalization, parenteral antimicrobial therapy, or pneumonia regardless of hospitalization). Infection risk factors were assessed using logistic regression.
Results
One hundred thirty-two patients were identified (78% male; median age, 71 years). The most common indications for ibrutinib were chronic lymphocytic leukemia (67%) and mantle cell lymphoma (12%). Infection and serious infection occurred in 94 (71%) and 47 (36%) patients, respectively; when pneumonia was excluded as a criterion for serious infection, the serious infection rate was 27%. The median time from ibrutinib initiation to first infection was 125 days. Prior allogeneic hematopoietic stem cell transplantation (allo-HSCT) (odds ratio [OR], 4.60; 95% CI, 1.22-17.4) and corticosteroid use (OR, 5.55; 95% CI, 1.52-20.3) were significant risk factors for serious infection. IFIs were diagnosed in 7 patients (5%): 5 had Pneumocystis jirovecii pneumonia and 2 were infected with invasive molds.
Conclusion
Serious infection and IFI rates are high but similar to those previously described. Risk factors for serious infection included allo-HSCT and corticosteroid use. Targeted antimicrobial prophylaxis should be evaluated in prospective studies in patients on ibrutinib to reduce serious infections and IFI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Department of Pharmacy, Huntsman Cancer Institute at the University of Utah Health, Salt Lake City, UT, USA.
- Division of Hematology and Hematologic Malignancies, Department of Medicine, Huntsman Cancer Institute at the University of Utah Health, Salt Lake City, UT, USA.
- Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Zitieren
APA
Tham, K., Prelewicz, S., deHoll, S., Stephens, D. M., & Gomez, C. A. (2024). Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies. American Journal of Health-System Pharmacy, 81(4), 112-119. https://doi.org/10.1093/ajhp/zxad210
Vancouver
Tham K, Prelewicz S, deHoll S, Stephens DM, Gomez CA. Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies. American Journal of Health-System Pharmacy. 2024;81(4):112-119. doi:10.1093/ajhp/zxad210
BibTeX
@article{Tham2024,
author = {Tham, Kenneth and Prelewicz, Stacy and deHoll, Sara and Stephens, Deborah M and Gomez, Carlos A},
title = {Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies},
journal = {American Journal of Health-System Pharmacy},
year = {2024},
volume = {81},
number = {4},
pages = {112--119},
doi = {10.1093/ajhp/zxad210}
}
EUVIMED